Stock Analysis

DexCom Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

  •  Updated
Source: Shutterstock

DexCom (NASDAQ:DXCM) Third Quarter 2022 Results

Key Financial Results
  • Revenue: US$769.6m (up 18% from 3Q 2021).
  • Net income: US$101.2m (up 16% from 3Q 2021).
  • Profit margin: 13% (in line with 3Q 2021).
  • EPS: US$0.26 (up from US$0.23 in 3Q 2021).
NasdaqGS:DXCM Earnings and Revenue Growth October 29th 2022

All figures shown in the chart above are for the trailing 12 month (TTM) period

DexCom Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 5.9%.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's shares are up 26% from a week ago.

Risk Analysis

You still need to take note of risks, for example - DexCom has 1 warning sign we think you should be aware of.

Valuation is complex, but we're helping make it simple.

Find out whether DexCom is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis